Athenex Inc

Athenex — Investor Presentation (September 2019)

29 slides from Athenex's investor presentation, Sep 9, 2019

  1. Slide 1: Athenex Corporate Presentation September 2019

    ATHENEX Corporate Presentation September 2019 CONFIDENTIAL Nasdaq: ATNX Exhibit 99.1

  2. Slide 2: Disclaimer

    2 Except for historical information, all of the statements, expectations, and assumptions contained in this presentation constitute forward-looking statements. These statements include descriptions regarding the intent, belief or current expectations of Athenex, Inc. (the “Company”), its officers or

  3. Slide 3: Global Biopharmaceutical Company Focused on Novel Oncology Therapies

    2 candidates with completed Phase III trials, preparing for NDA submission Oral paclitaxel and encequidar1: Phase III topline results reported in August 2019 showed statistically significant improvement in overall response rate over IV paclitaxel Tirbanibulin2 ointment: Phase III data reported in Ma

  4. Slide 4: Pipeline by program and indication

    Program Drug Candidate (1) Indication Pre-clinical Phase I Phase II Phase III U.S. & EU RoW Orascovery (P-gp inhibitor [encequidar] + chemoRx agents) Oral paclitaxel + encequidar (Oraxol) Metastatic breast cancer Angiosarcoma Oral paclitaxel + encequidar (Oraxol) with pembrolizumab Solid tumors Oral

  5. Slide 5: Phase III Pivotal Study in Metastatic Breast Cancer: Oral Paclitaxel ORR

    Orascovery Src Kinase Inhibition TCR-T Immunotherapy Arginine Deprivation Therapy Overview Commercial Platform Financials Phase III Pivotal Study in Metastatic Breast Cancer: Oral Paclitaxel had a Statistically Significant Improvement in Overall Response Rate over IV Paclitaxel Study met its primary

  6. Slide 6: Phase III Study Design: Oral Paclitaxel in Metastatic Breast Cancer

    An open-label, randomized, multicenter Phase III study to determine the safety, tolerability, and tumor response of oral paclitaxel and encequidar compared with IV paclitaxel in subjects with metastatic breast cancer (mBC) Primary Objectives To determine the safety and tolerability of oral paclitaxe

  7. Slide 7: Phase III Patient Population

    Phase III Pivotal Study of Oral Paclitaxel in Metastatic Breast Cancer Patient Population Orascovery Src Kinase Inhibition TCR-T Immunotherapy Arginine Deprivation Therapy Overview Commercial Platform Financials 402 patients ITT population (n) Typical metastatic breast cancer patients 2:1 randomizat

  8. Slide 8: Phase III Topline Results: Primary Endpoint ORR

    Phase III Pivotal Study of Oral Paclitaxel in Metastatic Breast Cancer Topline Results Population Oral Paclitaxel IV paclitaxel p-value ITT 36% 24% 0.01 Efficacy Results – Primary Endpoint: ORR Orascovery Src Kinase Inhibition TCR-T Immunotherapy Arginine Deprivation Therapy Overview Commercial Plat

  9. Slide 9: Topline Results: Secondary Endpoints PFS and OS

    Strong trend in progression-free survival (PFS) Strong trend in overall survival (OS) Proportion of confirmed responders with duration of response >150 days was 2.5 times higher for Oral Paclitaxel compared to IV paclitaxel Endpoint p-value Progression-free survival Strong trend favoring Oral Paclit

  10. Slide 10: Topline Results: Safety Results

    Phase III Pivotal Study of Oral Paclitaxel in Metastatic Breast Cancer Topline Results (cont’d) Orascovery Src Kinase Inhibition TCR-T Immunotherapy Arginine Deprivation Therapy Overview Commercial Platform Financials Lower incidence and severity of neuropathy compared to IV paclitaxel In the Oral P

  11. Slide 11: Summary of Topline Results

    Study met primary endpoint showing statistically significant improvement in overall response rate for Oral Paclitaxel compared to IV paclitaxel based on intent-to-treat (ITT) analysis Prior FDA feedback that this could be adequate to support an NDA Strong trend in progression-free survival (PFS) and

  12. Slide 12: Oral Paclitaxel and Encequidar Regulatory Pathway

    Plan to request a pre-NDA meeting as soon as possible Planned NDA submission Next Steps Investigate additional indications for Oral Paclitaxel as well as combinations with other anti-cancer drugs, including biologics and immuno-oncology drugs Look into the potential of this drug candidate in metrono

  13. Slide 13: Laying the Groundwork for Potential Commercialization

    Laying the Groundwork for Potential Commercialization of Oral Paclitaxel and Encequidar and for the Orascovery Platform Orascovery Src Kinase Inhibition TCR-T Immunotherapy Arginine Deprivation Therapy Overview Commercial Platform Financials Significant Progress Becoming Commercial Ready Continued r

  14. Slide 14: Significant Value Potential for Oral Paclitaxel and Encequidar

    Significant Value Potential for Oral Paclitaxel and Encequidar Orascovery Src Kinase Inhibition TCR-T Immunotherapy Arginine Deprivation Therapy Overview Commercial Platform Financials Paclitaxel is commonly used in the treatment of cancers Paclitaxel may be used in 47.9%1 of various types of cancer

  15. Slide 15: Orascovery Platform: Novel P-gp Pump Inhibitor Encequidar

    Note: Encequidar is the international nonproprietary name (INN) for HM30181A (1) Based on research and clinical studies to date Orascovery Platform: Novel P-gp Pump Inhibitor Encequidar Designed to Enable Oral Absorption of Chemotherapy Agents Chemotherapy Bioavailability Many chemotherapies are P-g

  16. Slide 16: P-gp Pump Inhibition May Result in Greater Drug Exposure

    Orascovery Platform P-gp Pump Inhibition may Result in Greater Drug Exposure and Better Tolerability than IV Pharmacokinetics model of oral paclitaxel 205 mg/m2 QDx3 weekly vs. IV paclitaxel 175 mg/m2 Q3W weekly; 1/3 weeks Orascovery Src Kinase Inhibition TCR-T Immunotherapy Arginine Deprivation The

  17. Slide 17: Other Significant Developments in Orascovery Platform

    Other Significant Developments in Orascovery Platform Drug Candidate Indication Pre-clinical Phase I Phase II Phase III Status / Milestone Oral paclitaxel + encequidar Angiosarcoma Received Orphan Drug Designation from US FDA (Apr 2018) Preliminary clinical study results released (May 2019) Recruite

  18. Slide 18: Oral Paclitaxel and Encequidar in Cutaneous Angiosarcoma

    Baseline 1 week of treatment 12 weeks of treatment (shows complete response) Baseline 6 weeks of treatment Orascovery Src Kinase Inhibition TCR-T Immunotherapy Arginine Deprivation Therapy Overview Commercial Platform Financials Oral Paclitaxel and Encequidar in Cutaneous Angiosarcoma Clinical Study

  19. Slide 19: Tirbanibulin Ointment for Actinic Keratosis

    Tirbanibulin Ointment for Actinic Keratosis Potential advantages of tirbanibulin ointment 1% Designed to have a short duration of dosing (5 days) Short duration Favorable safety data Majority of subjects treated to date experience mild to moderate LSR Novel mechanism of action Dual inhibition of Src

  20. Slide 20: Tirbanibulin Ointment for AK: Phase III Pivotal Studies

    Tirbanibulin Ointment for AK: Phase III Pivotal Studies Achieved Primary Endpoints Orascovery Src Kinase Inhibition TCR-T Immunotherapy Arginine Deprivation Therapy Overview Commercial Platform Financials Late Breaking Presentation of Topline Results at AAD 2019 KX01-AK-003 KX01-AK-004 % of Subjects

  21. Slide 21: Leadership in Actinic Keratosis: Almirall Collaboration

    Leadership in Actinic Keratosis Almirall and Athenex Collaboration and Additional Opportunities Almirall: Leading specialty company with a strong focus on skin health Headquartered in Spain Recently acquired Allergan dermatology assets in the U.S. Almirall: Recognized as the leader in the field of A

  22. Slide 22: TCR-T Immunotherapy Platform: Advantages of TAEST

    TCR-T Immunotherapy Platform: Advantages of TAEST Orascovery Src Kinase Inhibition TCR-T Immunotherapy Arginine Deprivation Therapy Overview Commercial Platform Financials Higher Binding Affinity of Engineered TCR High Expression Level of the TCR Highly Specific for Intended Target Cells Good Anti-T

  23. Slide 23: TAEST Pilot Studies Showed Encouraging Clinical Signals

    TAEST Pilot Studies Showed Encouraging Positive Clinical Signals TAEST monotherapy n=3 Patient 1 lung cancer SD, 6 months survival Patient 2 lung cancer SD, 10 months survival Patient 3 lung cancer Small tumor reduction, reduction in pain, softening of subQ metastasis Pilot dose escalation study bei

  24. Slide 24: PT01 (Pegtomarginase): Arginine Depletion Therapy

    PT01 (Pegtomarginase) Arginine depletion for ASS1/OTC deficient cancers An essential amino acid for cancer growth and survival Many solid tumors are deficient in ASS1 and/or OTC, hence dependent on external arginine supply ASS1 deficiency is significant in many common cancers such as Hepatocellular

  25. Slide 25: Global Supply Chain and Commercial Platforms

    The Taihao API plant in Chongqing, China voluntarily suspended production activities in May 2019. We chose to suspend production based on concerns raised by the Department of Emergency Management of Chongqing related to the location of our plant. We can provide no assurance of when, if at all, produ

  26. Slide 26: Pharmaceutical / Biotechnology Value Chain

    Pharmaceutical / Biotechnology Value Chain From R&D to Marketing Team: Experience (upstream and downstream integration) Molecular Target Identification (Academics) Marketing & Sales Infrastructure API / CMC R&D (Preclinical / Clinical) Athenex: Major Focus Global Supply Chain High Potency Drug Manuf

  27. Slide 27: Selected Q2 2019 & 2018 Financials

    Selected Q2 2019 & 2018 Financials ($ in millions) As of and for 3 Months Ended As of and for 6 Months Ended 6/30/2019 6/30/2018 06/30/2019 06/30/2018 Revenue 22.2 11.6 47.5 49.4 Product sales, net 22.0 11.5 47.2 24.1 Licensing revenue and consulting revenue 0.1 0.1 0.2 25.2 Grant revenue 0.1 0.0 0.

  28. Slide 28: Management Team with Deep Pharma & Biotech Experience

    Management Team with Deep Pharma & Biotech Experience Led the Development of Many Global Drugs Prior Experience Selected Drugs Developed Johnson Lau MBBS, MD, FRCP Chief Executive Officer, Chairman 25+ years experience Jeff Yordon Chief Operating Officer 45+ years experience Rudolf Kwan MBBS, MRCP C

  29. Slide 29: <x Co So

    <x Co So

Athenex — Investor Presentation (September 2019) on 6ix